Sarah Marler

Sarah Marler

Auto-generated profile, based on publicly available information

Sarah Marler

Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences; Vanderbilt University Medical Center at Village of Vanderbilt, 1500 21st Avenue South, Suite 2200, Nashville, Tennessee, 37212

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2019 in Frontiers in Psychiatry
Verified
Journal Article
Open access
BFBradley Ferguson
Bradley Ferguson
KDKristen Dovgan
Kristen Dovgan
DSDanielle Severns
Danielle Severns
SMShannon Martin
Shannon Martin
SMSarah Marler
Sarah Marler
DBDavid Beversdorf
David Beversdorf
Background: Many individuals with autism spectrum disorder (ASD) have significant gastrointestinal (GI) symptoms, but their etiology is currently unknown. Our prior work showed that GI symptoms correlated with stress reactivity, but the question remained as to the potential role of variations in diet in this relationship. Many families modify the diet of children with ASD, including diets with increased omega-3 fatty acids or diets free of gluten and/or casein, which may also impact GI symptoms and nutrition. However, little is known about the relationship between nutritional intake and GI symptomatology in ASD. The objective of this study was to assess the relationships between GI symptoms, omega-3 intake, micronutrients, and macronutrients in children with ASD. Methods: A total of 120 children diagnosed with ASD participated in this multisite study. A food frequency questionnaire was completed by the patient’s caretaker. The USDA Food Composition Database was utilized to provide nutritional data for the food items consumed by each participant. GI symptomatology was assessed using a validated questionnaire on pediatric gastrointestinal symptoms. Results: There were no significant associations between GI symptoms and the amount of omega-3 fatty acids and/or other micro and macro nutrients contained in the diet. Conclusions: This study suggests that dietary variations do not appear to drive GI symptoms, nor do GI symptoms drive dietary variations in those with ASD; although causation cannot be determined with this observational assessment. Further, there may be other factors associated with lower GI tract symptoms in ASD, such as increased stress response.

6 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
JSJoshua Ryan Smith
Joshua Ryan Smith
SLSeri Lim
Seri Lim
SBSnehal Bindra
Snehal Bindra
SMSarah Marler
Sarah Marler
BRBavani Rajah
Bavani Rajah
JLJames Luccarelli
James Luccarelli
Introduction: Catatonia is a highly morbid psychomotor and affective disorder which can affect autistic individuals with and without profound impairment. Catatonic symptoms are treatable with pharmacotherapy and electroconvulsive therapy, but the longitudinal effectiveness of these treatments has not been described. Methods: We conducted a prospective observational cohort study of patients with autism and co-morbid catatonia who received outpatient care in a specialized outpatient clinic from July 1 st , 2021 to May 31 st , 2024. Data investigating pharmacologic interventions, and clinical measures including the Bush Francis Catatonia Rating Scale (BFCRS), Kanner Catatonia Severity Scale (KCS), Kanner Catatonia Examination (KCE), and Clinical Global Impression – Improvement (CGI-I) were collected. Results: Forty-five patients were identified with 39 (86.7%) meeting criteria for profound autism. All patients received pharmacotherapy. 44 (97.8%) were treated with benzodiazepines with a mean maximal daily dose of 17.4 mg (SD=15.8) lorazepam equivalents. Thirty-five patients (77.8%) required more than one medication class for treatment. Fourteen patients (31.1%) attempted to taper off benzodiazepines during the study period; of these, 5 patients (11.1%) were successfully tapered off, and the remaining 9 (17.8%) discontinued the taper due to a return of catatonic symptoms. Statistically significant improvement was observed across all clinical domains except the KCS. However, the majority remained symptomatic over the study period. Conclusions: Despite clinical improvements while receiving the gold standard for psychopharmacologic management of catatonia, chronic symptoms remained for the majority of catatonia patients over the study period, and few were able to taper and discontinue benzodiazepine treatment. Lay Summary: Catatonia is a condition which can significantly impact the quality of life for autistic individuals with and without profound impairment. Symptoms of catatonia such as aggression and self-injury can improve with treatment. However, over the three-year period of this study, most patients experienced residual symptoms, and few could discontinue psychotropic medication.

8 September 2026 in Autism Research
Verified
Journal Article
Open access
PDF file
JSJoshua Ryan Smith
Joshua Ryan Smith
MBMaria Bonnee
Maria Bonnee
SMSarah Marler
Sarah Marler
SLSeri Lim
Seri Lim
DFD. Catherine Fuchs
D. Catherine Fuchs
JLJames Luccarelli
James Luccarelli
Catatonia occurs disproportionately in autistic individuals and may respond to electroconvulsive therapy (ECT), yet prior reports suggest greater treatment burden in this population. We compared longitudinal ECT utilization, safety, and clinical outcomes between autistic and non‐autistic patients with catatonia. This single‐center observational cohort included 110 patients treated from May 2022 through April 2026, comprising 43 autistic and 67 non‐autistic patients. Bush‐Francis Catatonia Rating Scale (BFCRS), Clinical Global Impression‐Improvement (CGI‐I), Clinical Global Impression‐Severity (CGI‐S), and Kanner Catatonia Severity and Examination scores were recorded across acute and maintenance treatment. Because the cohorts differed in age, biologic sex, and intellectual disability, treatment burden was evaluated using covariate‐adjusted, censoring‐aware models with a three‐level clinical‐group variable comprising non‐autism, autism with intellectual disability, and autism without intellectual disability. Autistic patients received more ECT sessions than non‐autistic patients (median, 35 vs. 14) over longer observed treatment courses (median, 342 vs. 97 days). After adjustment, this difference reflected longer retention in maintenance ECT rather than a higher treatment rate and was concentrated among autistic patients with intellectual disability (Cox hazard ratio, 0.21). Clinical improvement was observed in both cohorts: CGI‐I response occurred in 100.0% of autistic and 89.1% of non‐autistic patients, BFCRS reduction of at least 50% occurred in 76.9% and 75.4%, and CGI‐S improvement of at least 1 point occurred in 85.0% and 70.8%, respectively. Kanner total scores decreased significantly, and self‐injury prevalence declined from 42.9% to 17.1% among autistic patients. Combativeness improved in both cohorts, and documented adverse events were uncommon. ECT was associated with substantial clinical improvement in autistic and non‐autistic patients with catatonia. Autistic patients, particularly those with intellectual disability, experienced longer maintenance courses rather than more intensive treatment, underscoring the importance of sustained treatment access.

1 February 2025 in Experimental and Clinical Psychopharmacology
Verified
Journal Article
Open access
SMSarah Marler
Sarah Marler
MRMichael Rabbia
Michael Rabbia
KSKevin Sanders
Kevin Sanders
MDMichael Derks
Michael Derks
LBLorna Bailey
Lorna Bailey
HGHeather Guthrie
Heather Guthrie
Posttraumatic stress disorder (PTSD) has a significant impact on quality of life and affects more than 13 million individuals in the United States, with limited treatments available. EXUVIA (NCT05401565) was a Phase 2, randomized, placebo-controlled, double-blind trial, conducted across eight sites in the United States. The study aimed to assess the efficacy, safety, and pharmacokinetics of balovaptan, a highly selective vasopressin 1a receptor antagonist, in adults with PTSD. Between August 2022 and October 2023, a total of 57 adult participants (aged 18-60 years) were screened, and 29 participants were randomly allocated (1:1) to receive either balovaptan (13/29 [44.8%]) or placebo (16/29 [55.2%]). No meaningful differences were observed for balovaptan (-17.2 [± 10.7]) versus placebo (-15.6 [± 10.7]) as measured by the primary endpoint of change from baseline at Week 12 in Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition total symptom severity score. No meaningful differences for balovaptan versus placebo were observed at Week 12 for any secondary endpoints. Balovaptan was well tolerated with no new safety findings. The number of participants with at least one adverse event of any intensity was 9/13 (69.2%) in the balovaptan group and 7/16 (43.8%) in the placebo group. (PsycInfo Database Record (c) 2024 APA, all rights reserved).

12 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JSJoshua Ryan Smith
Joshua Ryan Smith
MBMaria Bonnee
Maria Bonnee
SMSarah Marler
Sarah Marler
RARowan Atwood
Rowan Atwood
BLBrianna Lewis
Brianna Lewis
PCPaul Croarkin
Paul Croarkin
Transcranial magnetic stimulation can provide noninvasive measures of cortical excitability and plasticity, but relationships between these measures and clinically observable features of autism are not fully characterized. Nineteen autistic participants aged 15 to 40 years were included in the analysis of a left primary motor cortex continuous theta-burst stimulation (cTBS) biomarker protocol. Motor evoked potentials were measured at baseline and at seven assessments from 5 to 60 min after stimulation. Linear mixed-effects models evaluated whether clinical measures moderated the post-stimulation motor evoked potential log-response ratio over time. Aberrant Behavior Checklist (ABC) and Attenuated Behavior Questionnaire (ABQ) analyses were restricted to the same 15 participants with caregiver-informant assessments. Catatonia severity, social impairment, ABQ Motor Total, ABQ Total, and cognitive ability did not significantly moderate the post-stimulation response. ABC Inappropriate Speech was associated with progressively greater post-stimulation facilitation (standardized Time-by-Inappropriate Speech interaction: beta = +0.688, SE = 0.210, 95% CI +0.276 to +1.099; Holm-adjusted P = .008 across eight informant-rated models). Two individual speech-related items ("Talks excessively" and "Talks to self loudly") survived false-discovery-rate correction. An exploratory eight-item ABC phenotype showed a large descriptive in-sample association (beta = +0.904, SE = 0.200, P less than .001) and directionally positive held-out performance. However, full-pipeline permutation tests were nonsignificant for both Pearson (r = .357, two-sided empirical P = .360) and Spearman correlations (rho = .446, two-sided empirical P = .261). Caregiver-rated inappropriate speech may be associated with altered post-cTBS motor cortical facilitation in autism. The candidate phenotype remains hypothesis-generating and requires independent validation.

28 August 2026 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Open access
PDF file
SLSeri Lim
Seri Lim
KKKaidi Kang
Kaidi Kang
EOElizabeth Oey
Elizabeth Oey
SSStephanie Santoro
Stephanie Santoro
CFCatherine Franklin
Catherine Franklin
JSJoshua Ryan Smith
Joshua Ryan Smith
Purpose: Down syndrome regression disorder (DSRD) is a condition occurring in young people with Down syndrome. It is associated with functional decline, new onset psychopathology, and increased support needs. DSRD is often associated with catatonia, for which electroconvulsive therapy (ECT) is an effective treatment. However, there are scant studies to guide best practice in this area. Methods: We report a case series of 5 patients who have received ECT at Vanderbilt University Medical Center. A systematic review and analysis were conducted, combining this case series with previously reported data in the literature. Results: This analysis included data from 27 patients, 5 from the VUMC case series and a further 22 from 14 studies. Combining all patients from case series and the systematic review, there were 17 pre-ECT and 15 post-ECT Bush Francis Catatonia Rating Scale (BFCRS) scores reported from 7 sites/studies. The mean pre-ECT BFCRS score from all patients was 17.40 (SD = 5.72) and the mean post-ECT BFCRS score was 4.40 (SD = 5.26). A generalized estimating equations analysis revealed that there was a significant difference in the expected BFCRS score before and after receiving ECT treatment ( β = -13.00 with 95%, p < 0.001), suggesting that the ECT treatment had a significant effect on reducing the BFCRS scores. No severe adverse events were reported. Conclusion: ECT is associated with clinical improvement in patients with catatonia in the context of DSRD in this systematic review and analysis. More research is needed to provide a more robust evidence base.